NovaMedica Strengthens its Team

Print 27 July 2016

Moscow, July 27, 2016 – Russian pharmaceutical company NovaMedica announces strengthening of its team. Elena Ilyina formerly holding one of the key positions in Sun Pharma (Ranbaxy) Russia is appointed as Vice President, Business Development.

 “Elena will be responsible for developing the Company’s portfolio built by the efforts of NovaMedica in-house R&D, as part of inlicensing deals and major strategic partnership with Pfizer,” commented Alexander Kuzin, Managing Director. “This function is strategically important for us as it’s the portfolio volume and structure that make pharmaceutical companies attractive in the marketplace.”

“I’m excited to join NovaMedica and become part of one of the strongest teams in the market,” said Elena Ilyina. “I hope to achieve impressive results working on the tasks set for me by the Company.”

Previously, Elena was responsible for marketing and sales of Sun Pharma (Ranbaxy) OTC drugs addressing strategic and tactical tasks faced by the OTC business. Elena has over 15 years of experience in key roles in the Russian and international pharmaceutical companies – Unipharm, Materia Medica, and Boehringer Ingelheim. She is a first-class professional with a proven track record in driving marketing, sales, and strategic product portfolio development, successful implementation of pharmaceutical business projects and ability to work efficiently in the changing market environment.

Elena is a business school graduate holding a degree from Baikal International Business School of Irkutsk State University (Siberian-American Management Department), Global Executive MBA from Vienna University of Economics and Business and University of Minnesota (2015).

About NovaMedica

NovaMedica is a modern Russian pharmaceutical company established in 2012 by leading U.S. venture capital firm Domain Associates LLC and RUSNANO, an investment fund that implements state policy for the development of Russia’s high-technology industries. NovaMedica has developed a well-established infrastructure to promote and sell pharmaceutical products in the Russian market. Its portfolio currently includes 25 products in ophthalmology and gastroenterology. NovaMedica's strategy is focused on the search, registration and localization in Russia of innovative pharmaceutical products and technologies, as well as the development of the company’s own research and development activities and the establishment of a GMP-compliant pharmaceutical production facility in Russia. NovaMedica is currently building a Technology Center in Moscow that will include R&D laboratories and production facilities for advanced technologies previously unavailable on the Russian pharmaceutical market. Learn more about NovaMedica at www.novamedica.com, follow us on Facebook and LinkedI

Return